Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/ASO.2005.03.023
Annals of Surgical Oncology 12:825-830 (2005)
© 2005 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McLoughlin, J. M.
Right arrow Articles by Kuhn, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McLoughlin, J. M.
Right arrow Articles by Kuhn, J. A.

Original Article

TNFerade, an Adenovector Carrying the Transgene for Human Tumor Necrosis Factor {alpha}, for Patients With Advanced Solid Tumors: Surgical Experience and Long-Term Follow-Up

James M. McLoughlin, MD1, Todd M. McCarty, MD1, Casey Cunningham, MD2, Valerie Clark, RN2, Neil Senzer, MD2, John Nemunaitis, MD2 and Joseph A. Kuhn, MD1

1 Department of Surgery, Sammons Cancer Center of Baylor University Medical Center, Worth Street #420, Dallas, Texas 75246
2 Mary Crowley Medical Research Center, Texas Oncology PA, 3500 Gaston Avenue, Dallas, Texas 75246

Correspondence: Address correspondence and reprint requests to: Todd M. McCarty, MD; E-mail: toddmc{at}baylorhealth.edu.

Background: Over the last several years, attempts have been made to use the tumoricidal effects of tumor necrosis factor (TNF)-{alpha} to treat cancer. Many of these studies demonstrated dose-limiting systemic side effects from high concentrations of TNF-{alpha}. The recent focus has been on developing a local delivery system for TNF-{alpha} to minimize the systemic response.

Methods: This study was part of a phase I open-label multi-institutional trial using TNFerade. We focus on the patients treated at Baylor University Medical Center and provide postoperative and long-term follow-up. TNFerade uses a second-generation nonreplicating adenovirus as the vector for delivery of the human transgene TNF-{alpha}. An early growth response 1 promoter was placed upstream from the TNF-{alpha} gene. This promoter is activated by ionizing radiation, thus allowing for temporal and spatial control of TNF-{alpha} release. Tumors were injected over 5 weeks with ionizing radiation given 3 days after injections for 6 weeks. Tumor response was measured by computed tomographic imaging and physical examination.

Results: As described in our original experience, no patients experienced dose-limiting toxicities up to doses of 4 x 1011 particles per injection. Tumors injected demonstrated a response independently of histology. Four patients had complete regression of the tumor injected. Three patients with complete regression have survived ≥2 years from the time of treatment.

Conclusions: Both short-term and long-term safety are observed with TNFerade. These data demonstrate the need for phase II trials.

Key Words: TNFerade • Tumor necrosis factor {alpha} • Adenovirus • Phase I




This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
W. Weber, W. Bacchus, M. Daoud-El Baba, and M. Fussenegger
Vitamin H-regulated transgene expression in mammalian cells
Nucleic Acids Res., September 27, 2007; 35(17): e116 - e116.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
D. Cross and J. K. Burmester
Gene therapy for cancer treatment: past, present and future.
Clin. Med. Res., September 1, 2006; 4(3): 218 - 227.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Society of Surgical Oncology.